Market Size & Trends
Estimated to be USD 1.97 billion in 2024, the animal health market in India is expected to rise at a CAGR of 13.9% from 2025 to 2030. Rising government participation, more product or service launches, a changing regulatory environment, startup culture development, higher R&D spending, and technical developments are the main drivers anticipated to shape the market. Strong government involvement, strategic worldwide alliances, and localized outreach initiatives define the sector. These advances are setting the foundation for a stronger and more effective animal healthcare system all around.
In March 2025, the Union Cabinet approved a revised Livestock Health and Disease Control Programme (LHDCP) with a budget of INR 3,880 crore (USD 453 Mn) for 2024-25 and 2025-26. The revamped scheme consists of three core componentsthe National Animal Disease Control Program (NADCP), Livestock Health & Disease Control (LH&DC), and the newly launched Pashu Aushadhi initiative. Key focus elements include mass vaccinations, deployment of mobile veterinary units, and distribution of affordable generic veterinary medicines through PM-Kisan Samriddhi Kendras (Centers) and cooperatives.
Earlier, in January 2025, the Indian Council of Agricultural Research (ICAR) organized a large-scale Animal Health Camp under the Scheduled Caste Sub-Plan (SCSP). Executed by the ICAR-Indian Institute of Soil & Water Conservation, this initiative provided veterinary services, raised health awareness, and promoted best practices in marginalized farming communities.
In November 2024, the Indian government launched the 'Animal Health Security Strengthening in India for Pandemic Preparedness and Response' project. With a USD 25 million grant from the G20 Pandemic Fund and implementation support from the ADB, World Bank, and FAO, the initiative aims to upgrade laboratory infrastructure, improve disease surveillance, and modernize data systems. Completion is slated for August 2026.
In July 2024, a significant regulatory shift occurred when the Indian Pharmacopoeia Commission (IPC) eliminated the obsolete Target Animal Batch Safety Test (TABST). This move not only minimizes unnecessary animal suffering but also aligns India with international standards in veterinary vaccine testing, reinforcing a commitment to humane and scientifically robust practices.
In May 2024, a Memorandum of Understanding was signed between the Department of Animal Husbandry and Dairying (DAHD) and the United Nations Development Programme (UNDP). Under this agreement, a digital AI-enabled system will monitor vaccine stocks, distribution, and storage. Additionally, DAHD will leverage UNDP’s Animal Vaccine Intelligence Network (AVIN) to enhance stakeholder capabilities, support livestock insurance, and improve immunization coverage. These cohesive policy actions and field-level interventions signal a major shift in India’s approach to animal health, promising improved outcomes, expanded service reach, and a sustainable framework for veterinary care.
Market Concentration & Characteristics
The degree of innovation can be characterized by bringing in high impact. The growing startups in the animal health industry of the country, along with the increasing government support for these companies, are responsible for this. For example, in March 2025, MimiBowBow, a Chennai-based startup, introduced India's first AI-powered pet health scan, Pet Scan Pro, enabling pet owners to detect early signs of illness with 95% accuracy using a smartphone.
The moderate impact of the merger & activities on the market can be seen owing to animal health companies in the country diversifying their product portfolio by acquiring specialized manufacturers of animal health products. For instance, in September 2024, SeQuent Scientific announced an INR 8,000 crore (USD 933 million) merger with Viyash Life Sciences to form one of India's largest animal pharmaceutical platforms.
The Government of India’s proactive regulatory role in animal healthcare is strengthening through updated standards aligned with international norms and strategic partnerships with organizations like the FAO and the UN. Recent initiatives—including the revised Livestock Health and Disease Control Programme with 3,880 crore (USD 453 million) budget, elimination of outdated safety tests, and AI-enabled vaccine monitoring via a DAHD-UNDP MoU—reflect a comprehensive approach to improving disease control, enhancing veterinary service delivery, and promoting humane, science-based practices. These measures, supported by large-scale vaccination drives, mobile veterinary units, and upgraded disease surveillance infrastructure, are transforming India’s animal health landscape toward greater efficiency, inclusivity, and pandemic preparedness.
The impact of product substitutes is estimated to be high. This is due to the fact that, despite the commanding presence of globally leading companies like Zoetis, Boehringer Ingelheim, Merck, Virbac, etc., a large number of domestic players exist in the country. According to 2022 reports from Pashudhan Praharee, a GoI magazine dedicated to publishing data on the country’s livestock industry, apart from the leading 10 companies, more than 50 domestic players currently operate in the Indian animal health industry.
The industry is subject to moderate-high impact from regional expansion activities by market players. Wherein, global leaders in the animal health industry, recognizing the expansion opportunities in India, are expanding their business in the country, and on the other hand, domestic companies are expanding their horizons beyond the country’s boundaries. For instance, in February 2025, Mars Inc., the world's largest veterinary clinic owner, entered the Indian market by acquiring a minority stake in a local veterinary business, Crown Veterinary Services. This move signals growing interest from global veterinary practice chains in India's expanding pet care sector.
Report Coverage & Deliverables
The PDF report & online dashboard will help you understand
- Competitive benchmarking
- Historical data & forecasts
- Company revenue shares
- Regional opportunities
- Latest trends & dynamics
Product Insights
The pharmaceuticals segment accounted for the largest revenue share of 42.55% in 2024. We further classify the segment into parasiticide, anti-infective, anti-inflammatory, analgesics, and other categories. The segment is leading because more animals are getting sick from food-related diseases, brucellosis, and diseases that can spread from animals to humans, creating a strong need for effective medicines and treatments. The analgesics segment under pharmaceuticals is estimated to grow at the highest rate due to increasing pre-operative as well as post-operative applications of these products in veterinary healthcare.
The other segment, containing veterinary telehealth, veterinary software, and livestock monitoring, is anticipated to grow at the fastest CAGR of 24.1% over the forecast period due to several factors. The growing adoption of these systems and increasing awareness about the benefits of using software solutions can be attributed to their growth. Furthermore, the prevalence of zoonotic and chronic diseases in animals and the rising adoption of IoT and artificial intelligence (AI) by animal owners are some of the major drivers for the segment's growth. The segment growth is also attributed to the rising usage among veterinarians to seek consultation from the veterinary specialist via telehealth tools to gain advice and insights regarding the care of the animal.
Animal Insights
The production animal segment dominated the market with a revenue share of 79.57% in 2024. The significant market share represented by the segment may be attributed to the fact that it has the largest livestock population in the world, as well as an increase in the government’s attention to increasing the production of animal-derived products, food safety, and sustainability. Total food security is a goal pursued by policymakers, like NITI Aayog, in the country, which promotes large-scale food production and increases the breeding of livestock. Policymakers prioritize long-term sustainability by enhancing productivity and prioritizing animal healthcare in production.
The companion animal segment is anticipated to grow at the highest growth rate over the forecast period owing to an increase in companion animal ownership, awareness, and demand for efficient animal care. An increase in companion animal ownership is due to the associated health benefits. Consequently, animal-assisted therapy is increasingly preferred as an adjuvant in several areas of animal healthcare. To maintain the well-being of companion animals, the adoption of pharmaceuticals and vaccines is increasing, thereby serving as a driver for the segment. In addition, increasing urbanization and growing disposable income have significantly raised companion animal ownership in both developed and developing regions.
End Use Insights
The veterinary hospitals & clinics segment dominated the market with a share of 71.74% in 2024. The presence of in-house laboratories in the veterinary hospitals and clinics is enabling faster diagnosis, helping patients avail of treatment at the earliest. In addition, the results of the clinical tests are easily available, which reduces the delay. Furthermore, the process of transporting pet patients from one location to another reduces the number of visits and time. Therefore, we anticipate significant growth in this segment throughout the forecast period. Availability of a wide range of treatments as well as diagnostic options in veterinary hospitals & clinics is a high-impact rendering driver for this segment.
The point-of-care testing/in-house testing segment is anticipated to grow at the highest rate over the forecast period, owing to an increase in the number of initiatives undertaken for animal healthcare and the availability of cost-efficient measures for disease diagnosis and monitoring. Examples of common veterinary point-of-care tests include cCRP, fructosamine, phenobarbital, lactate, hemoglobin, fibrinogen, pancreatic lipase, NH3, serum amyloid A (SAA), and T4 tests. These factors are anticipated to boost segment growth, as POC testing can help pet parents identify their pets’ health issues earlier, before they become serious or life-threatening.
Distribution Channel
The hospital/clinic pharmacy segment dominated the market with a share of 57.20% in 2024. High accessibility and affordability are the primary factors contributing to this substantial share. We expect the Hospital/Clinic Pharmacy segment to grow at a constant rate due to the increasing prevalence of chronic diseases. Furthermore, hospitals provide advanced treatment products, which are expected to contribute to the overall growth of the hospital segment. The rise in the adoption of companion pets worldwide is driving the segment's growth. Besides, high procedural volume because of frequent readmission of pets for treatment is one of the factors responsible for growth.
The e-commerce segment is anticipated to grow at the highest growth rate over the forecast period. Various advantages, including increased convenience for patients who may not be willing to purchase medicines from retail or hospital pharmacies, contribute to this growth. Moreover, these also facilitate a consistent supply of drugs, as medications can be preordered. We anticipate that these benefits will bolster the demand for e-commerce over the forecast period. Technological advancements, along with increasing pet adoption, are the main growth drivers. Increasing internet penetration is strengthening the smartphone-using population across the globe as it allows a better customer experience.
Key India Animal Health Companies Insights
Key players operating in the Indian animal health market are undertaking various initiatives to strengthen their presence and increase the reach of their products and services. Strategies such as expansion activities and partnerships are key in propelling the market growth.
Key India Animal Health Companies
- Merck & Co., Inc.
- Ceva
- Vetoquinol S.A.
- Zoetis
- Boehringer Ingelheim International GmbH
- Elanco Animal Health Incorporated
- IDEXX Laboratories, Inc.
- Neogen Corporation
- Virbac
- B. Braun Vet Care
- Covetrus, Inc.
- Avante Animal Health
- TeleVet
- Practo
- Mars Inc.
- Phibro Animal Health Corporation
- Dechra Pharmaceuticals Plc
- Bimeda Inc.
- Midmark Corporation
- Thermo Fisher Scientific
- IDVet
- Hester Biosciences Ltd
- India Immunologicals Ltd.
Recent Developments
-
In January 2025, The National Dairy Development Board (NDDB) of India, a government enterprise, announced the supply of over 339,000 units of various types of animal vaccines to Kenya.
-
In January 2025, JK Paper Ltd., which is a part of the paper and packaging industry, acquired Quadragen Vethealth Pvt. Ltd. (QVPL), an animal health products company, to expand into a new business sector of veterinary health.
-
In August 2024, Boehringer Ingelheim (BI) India and Vvaan Lifesciences Private Ltd. announced a partnership for the distribution rights of the former’s pet parasiticide product portfolio. BI signed this agreement as part of their India Animal Health Accelerated Growth Plan (AGP) initiative to strengthen their presence in the Indian market.
-
In June 2024, Max PetZ hospital in Delhi performed the nation’s first non-invasive heart surgery on a dog using the Transcatheter Edge-to-Edge Repair (TEER) technique.
-
In March 2024, scientists from IIT Guwahati completed the technology transfer of their innovative reverse genetic platform to develop vaccines for swine fever, which was employed by BioMed Pvt Ltd for commercialization. This technology has marked the launch of India’s first indigenously developed recombinant virus-based vaccine for classical swine fever.
India Animal Health Market Report Scope
|
Report Attribute |
Details |
|
Market size value in 2025 |
USD 2.19 billion |
|
Revenue forecast in 2030 |
USD 4.21 billion |
|
Growth rate |
CAGR of 13.9% from 2025 to 2030 |
|
Actual data |
2018-2023 |
|
Base year |
2024 |
|
Forecast period |
2025-2030 |
|
Quantitative units |
Revenue in USD million/billion, and CAGR from 2025 to 2030 |
|
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
|
Segments covered |
Product, animal, distribution channel, end-use |
|
Country scope |
India |
|
Key companies profiled |
Merck & Co., Inc.; Ceva; Vetoquinol S.A.; Zoetis; Boehringer Ingelheim International GmbH; Elanco Animal Health Incorporated; IDEXX Laboratories, Inc.; Neogen Corporation; Virbac; B. Braun Vet Care; Covetrus, Inc.; Avante Animal Health; TeleVet; Practo; Mars Inc.; Phibro Animal Health Corporation; Dechra Pharmaceuticals Plc; Bimeda Inc.; Midmark Corporation; Thermo Fisher Scientific; IDVet; Hester Biosciences Ltd; India Immunologicals Ltd. |
|
Customization scope |
We offer free report customization, equivalent to up to 8 analysts' working days, with every purchase. You can add or alter the scope of the country and segment. |
|
Pricing and purchase options |
Avail yourself of customized purchase options to meet your exact research needs. Explore purchase options |
India Animal Health Market Report Segmentation
This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the subsegments from 2018 to 2030. For this study, MIR has segmented the India animal health market report based on product, animal, distribution channel, and end-use
-
Product Outlook (Revenue, USD Million, 2018-2030)
-
Biologics
-
Vaccines
-
Modified/Attenuated Live
-
Inactivated (Killed)
-
Other Vaccines
-
-
Other Biologics
-
-
Pharmaceuticals
-
Parasiticides
-
Anti-infectives
-
Anti-inflammatory
-
Analgesics
-
Other Pharmaceuticals
-
-
Diagnostics
-
Consumables, reagents, and kits
-
Instruments and devices
-
-
Equipment & Disposables
-
Critical Care Consumables
-
Anesthesia Equipment
-
Fluid Management Equipment
-
Temperature Management Equipment
-
Rescue & Resuscitation Equipment
-
Research Equipment
-
Patient Monitoring Equipment
-
-
Medicinal Feed Additives
-
Other Products
-
Veterinary Telehealth
-
Veterinary Software
-
Livestock Monitoring
-
-
-
Animal Outlook (Revenue, USD Million, 2018-2030)
-
Production Animals
-
Poultry
-
Swine
-
Cattle
-
Sheep & Goats
-
Fish
-
-
Companion Animals
-
Dogs
-
Cats
-
Horses
-
Other Companion Animals
-
-
-
Distribution Channel Outlook (Revenue, USD Million, 2018-2030)
-
Retail
-
E-Commerce
-
Hospital/Clinic Pharmacy
-
-
End Use Outlook (Revenue, USD Million, 2018-2030)
-
Veterinary Reference Laboratories
-
Point-of-care Testing/In-house Testing
-
Veterinary Hospitals & Clinics
-
Others end use
-
Related Reports
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy